A gene expression predictor of response to EGFR-targeted therapy stratifies progression-free survival to cetuximab in KRAS wild-type metastatic colorectal cancer

Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK

(2008) M. Borner et al.   ANNALS OF ONCOLOGY

Cetuximab plus XELIRI or XELOX for First-Line Therapy of Metastatic Colorectal Cancer

(2008) Nicolas Moosmann et al.   Clinical Colorectal Cancer

Cetuximab plus oxaliplatin-based chemotherapy in the treatment of colorectal cancer

(2008) Nicolas Moosmann et al.   Expert Review of Anticancer Therapy

FLEX data, KRAS and ERCC1 testing in oncology

(2008) Justin Stebbing   Future Oncology

KRASMutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab

(2008) Astrid Lièvre et al.   JOURNAL OF CLINICAL ONCOLOGY

EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer

(2008) Alberto F. Sobrero et al.   JOURNAL OF CLINICAL ONCOLOGY

K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer

(2008) Christos S. Karapetis et al.   NEW ENGLAND JOURNAL OF MEDICINE